Kybernin P (Antithrombin Iii)

Antithrombin III in Kybernin P binds to and inactivates key clotting enzymes, primarily thrombin (factor IIa) and factor Xa. By enhancing the natural inhibition of these enzymes, it reduces the formation of fibrin clots and helps restore normal blood coagulation balance.

The dosage of Kybernin P is determined by the prescribing clinician based on the patient’s antithrombin activity, weight, clinical condition, and therapeutic goals. Only a qualified healthcare professional should set the appropriate dosing regimen.

Safety data for Antithrombin III in pregnancy or lactation are limited. The decision to use Kybernin P in these populations should be made by a qualified physician after weighing potential benefits against possible risks to the mother and child.

To order Kybernin P, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Kybernin P provides direct replacement of antithrombin activity, which is especially useful in patients with antithrombin deficiency or heparin resistance. Unlike heparin or direct oral anticoagulants, it does not rely on endogenous antithrombin levels and offers a targeted mechanism, but it requires intravenous administration and careful monitoring.

Kybernin P must be stored refrigerated at 2‑8 °C, protected from light, and must never be frozen or shaken. Prior to use, allow the product to reach room temperature if required, and follow aseptic techniques for intravenous preparation.

Kybernin P is administered by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and total dose are individualized based on the patient’s clinical status and laboratory monitoring of antithrombin activity.

Serious risks include severe allergic reactions such as anaphylaxis, unexpected bleeding or hemorrhage, and paradoxical thrombosis despite therapy. Patients should be monitored closely for signs of these events, and immediate medical attention is required if they occur.

Kybernin P should not be used in individuals with known hypersensitivity to antithrombin III products or any of the formulation components. Caution is also advised for patients with active, uncontrolled bleeding, severe liver disease, or those receiving incompatible anticoagulant regimens without proper monitoring.